Navigation Links
CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
Date:5/27/2008

PALO ALTO, Calif., May 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that two clinical abstracts have been accepted for presentation at the American Diabetes Association (ADA) 68th Scientific Sessions, which will be held in San Francisco, CA on June 6 - 10, 2008.

Ranexa(R) (ranolazine extended-release tablets)

Relationship Between Nonfasting Plasma Glucose Concentrations and Improved Glycemic Control in Patients with Diabetes and Coronary Artery Disease Treated with Ranolazine; Poster; Sunday, June 8, 2008, 12:00 - 2:00 p.m. and 6:15 - 7:30 p.m. PDT

Minority Angina Pectoris Patients at High Risk for Diabetes and Metabolic Syndrome; Poster; Sunday, June 8, 2008, 12:00 - 2:00 p.m. and 6:15 - 7:30 p.m. PDT

Additional information regarding the ADA 68th Scientific Sessions can be accessed at http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=58000.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeutics also has other clinical and preclinical drug development candidates and programs that have not been determined to be safe or effective in humans for any uses.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... first brain mirroring wellness product via Kickstarter campaign on June 15th to fund ... already pre-ordered the B2v2, exceeding the original Kickstarter goal by more than 150% ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... DuPont gains exclusive rights to the ERS patent portfolio covering CRISPR-Cas genome editing ... commercialize the foundational intellectual property (IP) of the CRISPR-Cas technology from co-inventor and ...
(Date:6/26/2017)... ... ... Two new members were elected to the University City Science Center’s Board ... J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at Temple ... Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, as ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... of a redesigned, easier-to-navigate website for all six of their healthcare job ... nurses, dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and the ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):